Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / OVID - Ovid Therapeutics: Good Entry Point For Investors

OVID - Ovid Therapeutics: Good Entry Point For Investors

Ovid Therapeutics Inc.
  • There are promising results for OV-935 in patients with Dravet Syndrome, with questionable results in patients with Lennox-Gastaut Syndrome (LGS).
  • Pipeline drug OV-935 shows high revenue potential.
  • The stock is at a good entry price today, but there is high risk with phase 3 clinical trials ahead.
  • OV-935 competitors show limitations, indicating room in the market for a superior Anti-Epileptic Medication.

For further details see:

Ovid Therapeutics: Good Entry Point For Investors
Stock Information
Company Name: Ovid Therapeutics Inc.
Stock Symbol: OVID
Market: NASDAQ
Website: ovidrx.com
Menu
OVID OVID Quote OVID Short OVID News OVID Articles OVID Message Board
Get OVID Alerts

News, Short Squeeze, Breakout and More Instantly...